

Technical Information Report

AAMI/ISO TIR11137-4: 2022

Sterilization of health care
products—Radiation—Part
4: Guidance on process
control

Sterilization of health care products—Radiation— Part 4: Guidance on process control

Approved 25 January 2022 by
AAMI

Approved 12 June 2022 by
American National Standards Institute, Inc.

Abstract: Provides additional guidance to that given in ISO 11137-3 on meeting the requirements specified in ISO 11137-1, ISO 11137-2 and ISO/TS 13004 for the establishment and control of a radiation sterilization process using gamma, electron beam, and X-irradiation.

Keywords: radiation sterilization, gamma, electron beam, X-irradiation

Published by

AAMI
901 N. Glebe Road, Suite 300
Arlington, VA 22203
www.aami.org

© 2022 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of ISO and AAMI. No part of this publication may be reproduced or distributed in any form, including an electronic retrieval system, without the prior written permission of AAMI. All requests pertaining to this document should be submitted to AAMI. It is illegal under federal law (17 U.S.C. § 101, et seq.) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violator's risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, visit the [Copyright Clearance Center](https://www.copyright.com).

Printed in the United States of America

ISBN 978-1-57020-839-3

AAMI Technical Information Report

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that, although both standards and TIRs are periodically reviewed, a standard must be acted on—reaffirmed, revised, or withdrawn—and the action formally approved usually every five years but at least every 10 years. A TIR must be acted on and the action formally approved usually every three years.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

CAUTION NOTICE: This AAMI TIR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 901 N. Glebe Road, Suite 300, Arlington, VA 22203-1633.

ANSI Registration

Publication of this Technical Report that has been registered with ANSI has been approved by the Accredited Standards Developer (AAMI, 901 N. Glebe Road, Suite 300, Arlington, VA 22203). This document is registered as a Technical Report according to the Procedures for the Registration of Technical Reports with ANSI. This document is not an American National Standard and the material contained herein is not normative in nature.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 901 N. Glebe Road, Suite 300, Arlington, VA 22203.

Contents

Page

Committee representation.....	vi
Background of AAMI adoption of ISO/TS 11137-4:2020.....	x
Foreword.....	xi
Introduction	xii
1 Scope.....	1
2 Normative references.....	1
3 Terms, definitions, and symbols.....	1
4 Principles applied in validating and controlling an irradiation process.....	4
5 Establishing process target doses.....	6
6 Routine monitoring and control	18
7 Release of product from the irradiation process.....	29
8 Maintaining process effectiveness	30
Annex A (informative) Examples of setting process target dose ranges and interpretation of process output.....	31
Bibliography	53

List of Tables

Table 1—Process parameters critical to radiation sterilization.....	6
Table 2—Potential components of σ_{process} and actions to reduce them.....	13
Table A.1—Example matrix	31
Table A.2—Example 1 dose mapping data.....	32
Table A.3—Example 1 dose mapping ratios	32
Table A.4—Example 1 dose and ratio averages.....	32
Table A.5—Example 2 dose mapping data.....	37
Table A.6—Example 2 dose mapping ratios	37
Table A.7—Example 2 dose and ratio averages.....	37
Table A.8—Example 3 dose mapping data.....	41
Table A.9—Example 3 dose mapping ratios	41
Table A.10—Example 3 dose and ratio averages.....	41
Table A.11—Example 4 dose mapping data averages	45
Table A.12—Example 4 dose mapping ratios averages	45
Table A.13—Example 4 rules for investigation.....	48
Table A.14—Example 5 dose mapping data.....	49
Table A.15—Example 5 dose mapping ratios	49
Table A.16—Example 5 dose and ratio averages.....	49

List of Figures

Figure 1—Inputs and steps in establishing a process target dose	7
Figure 2—Components of σ_{process}	11
Figure 3—Acceptance range based on $D_{\text{mon}}^{\text{ster}}$ and $D_{\text{mon}}^{\text{max,acc}}$	23
Figure 4—Process acceptance ranges with action and alert levels	24

Figure 5—Expected probability distribution functions for an example process where D_{target} is set to $D_{\text{target}}^{\text{lower}}$	25
Figure 6—Monitoring dosimeter value histogram for an example process.....	27
Figure 7—Process control chart for an example irradiator, trended over time	29
Figure A.1—Variation of minimum and maximum dose to product during operation at $D_{\text{target}} = D_{\text{target}}^{\text{lower}}$ (solid line) and $D_{\text{target}} = D_{\text{target}}^{\text{upper}}$ (dashed line) for both steady state and with transitions taken into consideration	35
Figure A.2—Variation of dose to the monitoring position during steady state operation at the chosen process target dose for an acceptance range between $D_{\text{mon}}^{\text{ster}}$ and $D_{\text{mon}}^{\text{max,acc}}$	36
Figure A.3—Variation of minimum and maximum dose to product during operation at $D_{\text{target}} = D_{\text{target}}^{\text{lower}}$ (solid line) and $D_{\text{target}} = D_{\text{target}}^{\text{upper}}$ (dashed line).....	39
Figure A.4—Variation of dose to the monitoring position during operation at the chosen parameters for an acceptance range between $D_{\text{mon}}^{\text{ster}}$ and $D_{\text{mon}}^{\text{max,acc}}$	40
Figure A.5—Variation of doses to minimum and maximum in product and expected variation of monitoring dose during operation at $D_{\text{target}} = D_{\text{target}}^{\text{lower}}$	43
Figure A.6—Variation of dose to the monitoring positions during operation at the chosen parameters for an acceptance range based on process monitoring	44
Figure A.7—Variation of minimum and maximum dose to product during operation at $D_{\text{target}} = D_{\text{target}}^{\text{lower}}$ (solid line) and $D_{\text{target}} = D_{\text{target}}^{\text{upper}}$ (dashed line).....	47
Figure A.8—Variation of dose to the monitoring position during operation at the chosen parameters for an acceptance range based on alert and action levels.....	48
Figure A.9—Variation of minimum and maximum dose to product during operation at $D_{\text{target}} = D_{\text{target}}^{\text{lower}}$ (solid line) and $D_{\text{target}} = D_{\text{target}}^{\text{upper}}$ (dashed line).....	51
Figure A.10—Variation of dose to the monitoring position during operation at the chosen parameters for an acceptance range based on action and alert levels.....	52

Committee representation

Association for the Advancement of Medical Instrumentation

AAMI Radiation Sterilization Working Group

The adoption of ISO/TS 11137-4 as an AAMI Technical Information Report was initiated by the AAMI Radiation Sterilization Working Group. AAMI ST-WG02 provides input to the AAMI Sterilization Standards Committee which is the responsible group for providing the U.S. input to the relevant group in the International Organization for Standardization (ISO). U.S. representatives from Radiation Sterilization Working Group and the TAG played an active part in developing the ISO document.

At the time this document was published, the **AAMI Radiation Sterilization Working Group** had the following members:

Cochairs: Emily Craven
Elaine Daniell

Members: Jennifer Asleson, Quality, Microbiology & Sterilization Services LLC
Dean Bird, Olympus America Inc
Jody Birks, Eagle Medical Inc
Tim Bollnow, Intuitive Surgical Inc
Carolyn Braithwaite-Nelson, Philips
Trabue Bryans, BryKor LLC
Nicholas Brydon, Nick Brydon Consulting LLC
Richard Burgess, BSI Healthcare
Robb Calabro, AbbVie
Glenn Calvert, West Pharmaceutical Services, Inc.
Denise Cleghorn, Boston Scientific Corporation
Gary Cranston, Consulting & Technical Services/PCS
Greg Crego, IUVO BioScience
Elaine Daniell, EDan-SA LLC
Douglas Davie, Sterilization Validation Services
Brian Davis, Stryker Instruments Division
Jeffrey DelGaudio, Cardinal Health
Niki Fidopiastis, NAMSA
Lisa Foster, Adiuvo QS & SA Consulting
Chad Geiger, DexCom Inc
Jacob Gibbons, Genentech Inc
Amy Gravley, DEKRA Certification
Michael Graybill, 3M Health Care
Chris Haas, Getinge USA
Douglas Harbrecht, Sterility Assurance LLC
Deborah Havlik, DA Havlik Consulting
Trang Hoang, Edwards Lifesciences
Mollie Holter, MicroBio Consulting LLC
Crystal Hostler, Mesa Laboratories
Betty Howard, STERIS Corporation
Ezra Koski, Terumo BCT
Mark Krocko, Mevex Corporation
Vu Le, Abbott Laboratories
John Logar, Johnson & Johnson
Randy Mack, Pfizer Parenteral Center of Excellence
Ilva Mane, Medline Industries Inc
Jeffrey Martin, Sterilization and Quality System Consulting LLC
Mauricio Martinez, Smiths Medical
Patrick McCormick, Bausch & Lomb Inc
Susan Messier, Ethide Laboratories
Larry Nichols, Steri-Tek
Susumu Nozawa, Siemens Healthineers
Gerry O'Dell, Gerry O'Dell Consulting

Kevin O'Hara, Sotera Health LLC
David Parente, Sterwell LLC
Kimberly Patton, Becton Dickinson & Company
Rudy Pina, Dynatec Scientific Labs Inc
Keith Reiner, Terumo Americas Corporate
Tyrone Rouse, Owens & Minor
Jody Rupert, WL Gore & Associates Inc
Manuel Saavedra, Avanos Medical
Mara Senescu, Baxter Healthcare Corporation
Harry Shaffer, Sterilization Consulting Services
Molly Swanson, Quality Tech Services LLC
Justin Tettenborn, Fresenius Medical Care
Stephanie Volk, ConvaTec Inc
Richard Weisman, Fresenius Medical Care
Scott Weiss, Alcon Laboratories Inc
Patrick Weixel, FDA/CDRH
Beverly Whitaker, Indigo Consulting Group LLC
James Whitcomb, LexaMed Ltd
John Williams, Medtronic Inc Campus
Jarl Yeager, Powder River Medical Resources
Shelley Zimmerman, WuXi AppTec Inc

Alternates: Christopher Anderson, Johnson & Johnson
Kenneth Aston, Intuitive Surgical Inc
Agnieszka Baczek, Medline Industries Inc
Curt Bogue, Cook Medical
David Brodersen, Getinge USA
Casey Butcher, Fresenius Medical Care
Emily Craven, Boston Scientific Corporation
Martin Dawson, BSI Healthcare
Zachary Dukerich, Arthrex Inc
Gordon Ely, LexaMed Ltd
Shawn Engberg, MD Furniture & Supply
Niki Fidopiastis, Medtronic Inc Campus
Michael Groendyk, West Pharmaceutical Services, Inc.
Nichole Jackson, Ecolab
Tara Jacobson, Abbott Laboratories
Satu King, Philips
Sarath Koruprolu, Ethide Laboratories
Cathy Leckwart, WuXi AppTec Inc
James Maher, Becton Dickinson & Company
Consuelo McChesney, Alcon Laboratories Inc
Tom McElroy, IUVO BioScience
Nicole McLees, 3M Health Care
Philip Myers, Alcon Laboratories Inc
Dupeh Palmer-Ochieng, FDA/CDRH
Michelle Pierce, NAMSA
Kyrstan Polaski, STERIS Corporation
Michael Schoene, Bausch & Lomb Inc
Kristen Spigiel, Stryker Instruments Division
Sopheak Srun, Quality Tech Services LLC
Peter Veselovsky, Mevex Corporation
Wendy Wangsgard, WL Gore & Associates Inc
Jill Warren, Siemens Healthineers
Martell Winters, Sotera Health LLC
Dan Wojtczak, Baxter Healthcare Corporation

NOTE Participation by federal agency representatives in the development of this document does not constitute endorsement by the federal government or any of its agencies.

At the time this technical information report was published, the **AAMI Sterilization Standards Committee** had the following members:

Cochairs: Janet Prust
Patrick Weixel

Members: Gregory Aldrich
Anas Aljabo, CMC Sterilization Ltd
Eseosa Tony Amenaghawon
Brett Anderson, Cochlear Ltd
Jennifer Asleson, Quality, Microbiology & Sterilization Services LLC
Richard Bancroft, STERIS Corporation
Marie Brewer, St Luke's Hospital of Cedar Rapids
Trabue Bryans, BryKor LLC
Jonathan Burdach, Nanosonics Limited
Charles Cogdill, Medtronic Inc Campus
Emily Craven, Boston Scientific Corporation
Jacqueline Daley, Providence St Joseph Health System
Gordon Ely, LexaMed Ltd
Nicole Felderman, CIVCO Medical Solutions
Brian Fortier, Aorta Medical Inc
Lisa Foster, Adiuvo QS & SA Consulting
Daniel Fowler, WuXi AppTec Inc
Joel Gorski, NAMSA
Magnus Graham, BSI Healthcare
Ashley Hammer
Joyce Hansen, Johnson & Johnson
Douglas Harbrecht, Sterility Assurance LLC
John Harper, Sterile Edge
Deborah Havlik, DA Havlik Consulting
Mollie Holter, MicroBio Consulting LLC
Clark Houghtling, Cosmed Group Inc
Susan Klacik, HSPA
Erin Kyle, Association of Perioperative Registered Nurses (AORN)
Byron Lambert, Abbott Laboratories
Emily Lorcheim, ClorDiSys Solutions, Inc
Patrick McCormick, Bausch & Lomb Inc
Leslie Nichols, Mayo Clinic
Gerry O'Dell, Gerry O'Dell Consulting
Tarika Onishi, DexCom Inc
Ken Paddock, Baxter Healthcare Corporation
Kia Parker
Kimberly Patton, Becton Dickinson & Company
Janet Prust, 3M Health Care
Nancy Rakiewicz, IUVO BioScience
Joan Rickard
Linda Schultz
Kristen Singleton, Getinge USA
Joan Spear, Joan M. Spear (Independent Expert)
Sopheak Srun, Quality Tech Services LLC
Mark Swanson, Quality and Regulatory Expert Partners (QRX)
Julie TerWee, Pfizer Parenteral Center of Excellence
James Treharn
Marjorie Wall, Kaiser Permanente Foundation
Sean Weir
Patrick Weixel, FDA/CDRH
James Wiggs
Martell Winters, Sotera Health LLC
Roberto Zumbado, Philips

Alternates: Jennifer Benolken, DuPont Tyvek Medical and Pharmaceutical Protection
Stacy Bohl, Boston Scientific Corporation
Carolyn Braithwaite-Nelson, Philips
Richard Burgess, BSI Healthcare

Greg Crego, IUVO BioScience
Kimbrell Darnell, Becton Dickinson & Company
Aaron DeMent, Sotera Health LLC
Eric Einwalter, CIVCO Medical Solutions
Chad Geiger, DexCom Inc
Anna Grayson, Grayson Associates
David Kelman, Sterile Edge
Michelle (Shelly) Luebke, Baxter Healthcare Corporation
Gerald McDonnell, Johnson & Johnson
David McGoldrick, Abbott Laboratories
Nicole McLees, 3M Health Care
Shane Pinkston, Getinge USA
Christine Render, Cosmed Group Inc
Jimmy Reyes, Alcon Laboratories Inc
Molly Swanson, Quality Tech Services LLC
Lisa Ward, STERIS Corporation
Jon Wood, HSPA
Shelley Zimmerman, WuXi AppTec Inc

NOTE Participation by federal agency representatives in the development of this technical information report does not constitute endorsement by the federal government or any of its agencies.

Background of AAMI adoption of ISO/TS 11137-4:2020

As indicated in the foreword to the main body of this document (page xiii), the Organization for Standardization (ISO) is a worldwide federation of national standards bodies. The United States is one of the ISO members that took an active role in the development of this standard, which was developed by ISO/TC 198 to additional guidance to that given in ISO 11137-3 on meeting the requirements specified in ISO 11137-1, ISO 11137-2 and ISO/TS 13004 for the establishment and control of a radiation sterilization process using gamma, electron beam, and X-irradiation.

U.S. participation in ISO/TC 198 is organized through the U.S. Technical Advisory Group to ISO/TC 198 administered by the Association for the Advancement of Medical Instrumentation. Experts from the United States made a considerable contribution to this document.

AAMI/ISO TIR11137-4 was registered by the American National Standards Institute (ANSI) on 12 June 2022.

AAMI and ANSI procedures require that standards be reviewed every five years and, if necessary, revised to reflect technological advances that may have occurred since publication. AAMI procedures require that technical information reports are reviewed every three years.

AAMI (and ANSI) have adopted other ISO standards and technical reports.

As used within the context of this document, “shall” indicates requirements strictly to be followed to conform to the recommended practice. “Should” indicates that among several possibilities, one is recommended as particularly suitable, without mentioning or excluding others, or that a certain course of action is preferred but not necessarily required, or that (in the negative form) a certain possibility or course of action should be avoided but is not prohibited.

“May” is used to indicate that a course of action is permissible within the limits of the recommended practice. “Can” is used as a statement of possibility and capability. Finally, “must” is used only to describe “unavoidable” situations, including those mandated by government regulation.

NOTE Users of this technical information report are advised that this document is an AAMI identical adoption of an ISO document and that the following international conventions have been carried over to the AAMI publication:

- British English spelling (e.g., colour instead of color);
 - Use of SI units (e.g., metres instead of feet, Celsius instead of Fahrenheit, etc.);
 - Decimal comma instead of a decimal point (e.g., 1 000,15 instead of 1,000.15).
-

The concepts incorporated in this standard should not be considered inflexible or static. This standard, like any other, must be reviewed and updated periodically to assimilate progressive technological developments. To remain relevant, it must be modified as technological advances are made and as new data come to light.

Suggestions for improving this standard are invited. Comments and suggested revisions should be sent to Standards Department, AAMI, 901 N. Glebe Road, Suite 300, Arlington, VA 22203.

NOTE Beginning with the ISO foreword on page xi AAMI/ISO TIR11137-4:2022, *Sterilization of health care products—Radiation—Part 4: Guidance on process control* is identical to ISO/TS 11137-4:2020.

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 198, *Sterilization of health care products*.

A list of all parts in the ISO 11137 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

ISO 11137-1 describes the requirements for the development, validation and routine control of a radiation sterilization process, and ISO 11137-3 gives guidance on dosimetric requirements in all stages of this development, validation, and control. The purpose of ISO/TS 11137-4 is to provide additional guidance on the establishment and control of the irradiation process, including setting process target doses and verifying that the process is in a state of control.

This document addresses the establishment of methods to set process target doses and verify the process is in a state of control. Dosimetry is used during the validation of a radiation sterilization process to measure doses, and the interpretation of dosimetry results from operational and performance qualification studies is critical in establishing a process that will meet the requirements specified for minimum and maximum dose as outlined in ISO 11137-1, ISO 11137-2, and ISO/TS 13004.

Routine dosimetry is used to monitor that the process is in a state of control and dose specifications have been met. One purpose of this technical specification is to provide guidance on the application of a dose measurement as a tool used for monitoring an irradiation process using statistical techniques.

The guidance given is not normative and is not provided as a checklist for auditors. The guidance provides explanations and methods that are regarded as being suitable means for achieving conformity with the minimum and maximum dose specifications. Methods other than those given in the guidance may be used, if they are effective in achieving conformity with the requirements of ISO 11137-1, ISO 11137-2, and ISO/TS 13004.

Sterilization of health care products—Radiation—

Part 4: Guidance on process control

1 Scope

This document provides additional guidance to that given in the International Organization for Standardization (ISO) 11137-3 on meeting the requirements specified in ISO 11137-1, ISO 11137-2 and ISO/TS 13004 for the establishment and control of a radiation sterilization process using gamma, electron beam, and X-irradiation.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 11137-1:2006, Sterilization of health care products — Radiation — Part 1: Requirements for development, validation, and routine control of a sterilization process for medical devices

ISO 11137-3:2017, Sterilization of health care products — Radiation — Part 3: Guidance on dosimetric aspects of development, validation, and routine control

3 Terms, definitions, and symbols

For the purposes of this document, the terms and definitions given in ISO 11137-1, ISO 11137-3 and the following apply.

ISO and International Electrotechnical Commission (IEC) maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <http://www.iso.org/obp>;
- IEC Electropedia: available at <http://www.electropedia.org/>.

3.1

acceptance range

range within which the statistic under consideration lies with a specified probability when the process is in a state of control

3.2

action level

value from monitoring that necessitates immediate intervention

[SOURCE: ISO 11139:2018, 3.5]

3.3

alert level

value from monitoring providing early warning of deviation from specified conditions

Note 1 to entry: An alert level value provides early warning of a potential deviation for a process under control. Although further action is not required, increased supervision of the process is recommended.

[SOURCE: ISO 11139:2018, 3.11, modified — Note 1 to entry has been added.]

3.4

cycle time

period of time an irradiation container spends in each dwell position in a gamma process, used as a control parameter for dose

Note 1 to entry: Cycle time can also apply to x-ray and could also include the time required to move between dwell positions.

[SOURCE: ISO 11139:2018, 3.73, modified — Note 1 to entry has been added.]

3.5

influence quantity

quantity that, in a direct measurement, does not affect the quantity that is actually measured, but affects the relation between the indication and the measurement result

Note 1 to entry: In radiation processing dosimetry, this term includes temperature, relative humidity, time intervals, light, radiation energy, absorbed-dose rate, and other factors that might affect dosimeter response, as well as quantities associated with the measurement instrument.

[SOURCE: VIM 2012, 2.52, modified — Note 1 to entry added from ISO/ASTM 52701:2013.]

3.6

measurement uncertainty

parameter, associated with the result of a measurement, that characterizes the dispersion of the values that could reasonably be attributed to the measurand

3.7

process control

specific activities to ensure process requirements are achieved

[SOURCE: ISO 11139:2018, 3.209]

3.8

process load

volume of material with a specified product loading configuration irradiated as a single entity

Note 1 to entry: The process load consists of one or more irradiation containers.

[SOURCE: ISO/ASTM 52303:2015, 3.1.10]

3.9

process target dose

D_{target}

dose, at a specified monitoring location, which the irradiation process parameters are set to deliver

3.10

process variability

measure of factors that result in a random distribution of data around the average that provides information on how well the process can perform when all special cause variation is removed

3.11

statistical process control

SPC

set of techniques for improving the quality of process output by reducing variability through the use of one or more control charts and a corrective action strategy used to bring the process back into a state of statistical control

[SOURCE: ASTM E2587-16]

3.12

targeting buffer

standard factor or factors used to determine process target doses which has been demonstrated to be more conservative calculated values of UF_{lower} and UF_{upper} during historical routine processing

3.13 Symbols

Symbol	Meaning
D_{min}	direct measurement of minimum dose in a given irradiation container
D_{max}	direct measurement of maximum dose in a given irradiation container
D_{mon}	direct measurement of dose at the routine monitoring position
D_{ster}	Sterilization dose determined in accordance with ISO 11137-1:2006, 8.2
$D_{max,acc}$	maximum acceptable dose determined in accordance with ISO 11137-1:2006, 8.1
$D_{min}^{limit} = D_{ster} * UF_{lower}$	calculated dose at the minimum dose position used for establishing process parameters that ensures at a specified level of confidence that D_{ster} is met or exceeded during routine processing
$D_{max}^{limit} = D_{max,acc} * UF_{upper}$	calculated dose at the maximum dose position used for establishing process parameters that ensures at a specified level of confidence that $D_{max,acc}$ is not exceeded during routine processing
$UF_{lower} = 1/(1 - k * \sigma_{process}^{min}/100)$	process factor used to calculate D_{target}^{lower} and D_{min}^{limit} (where $\sigma_{process}^{min}$ is expressed as a percentage)
$UF_{upper} = 1/(1 + k * \sigma_{process}^{max}/100)$	process factor used to calculate D_{target}^{upper} and D_{max}^{limit} (where $\sigma_{process}^{max}$ is expressed as a percentage)
$R_{min/mon} = D_{min} / D_{mon}$	ratio of minimum to monitor dose determined by dose mapping
$R_{max/mon} = D_{max} / D_{mon}$	ratio of maximum to monitor dose determined by dose mapping
$D_{mon}^{ster} = D_{ster}/R_{min/mon}$	dose at the monitoring position that correlates to the sterilization dose specification
$D_{mon}^{max,acc} = D_{max,acc}/R_{max/mon}$	dose at the monitoring position that correlates to maximum acceptable dose specification
$D_{target}^{lower} = D_{min}^{limit} / R_{min/mon}$	calculated dose at the routine monitoring position used for establishing process parameters that ensures at a specified level of confidence that D_{ster} is met or exceeded during routine processing
$D_{target}^{upper} = D_{max}^{limit} / R_{max/mon}$	calculated dose at the routine monitoring position used for establishing process parameters that ensures at a specified level of confidence that $D_{max,acc}$ is not exceeded during routine processing
σ_{cal}	component of uncertainty related to the calibration of the dosimetry system including the uncertainty reported by the calibration laboratory, uncertainty in the mathematical fit of the calibration function, and uncertainties due to influence quantities, but excluding components due to the reproducibility of the dosimeter measurement (see σ_{rep})
σ_{mach}	component of variability related to the radiation source and conveyor system
σ_{map}	component of variability measured during a dose mapping exercise

Symbol	Meaning
σ_{process}	standard deviation associated with the irradiation process used for setting process target doses: $\sigma_{\text{process}}^{\text{max}}$ — The standard deviation associated with the process maximum dose $\sigma_{\text{process}}^{\text{min}}$ — The standard deviation associated with the process minimum dose
σ_{rep}	component of variability associated with the reproducibility of the dosimeter measurement

4 Principles applied in validating and controlling an irradiation process

4.1 General

Many dose measurements are made in the validation of an irradiation process as described in ISO 11137-1 and ISO 11137-3. These measurements are used to establish a relationship between processing parameters, monitoring dose, and the range of doses to a product, and to characterize the variability associated with the process itself. These measurements are made with calibrated dosimetry systems traceable to internationally recognized standards with a known level of uncertainty.

It is a requirement to monitor that the validated radiation sterilization process is in a state of control. ISO 11137-1:2006, 10.6 requires the use of dosimeters in routine monitoring and control and provides guidance on the additional review of monitoring of process parameters when determining that product has been processed according to specification.

The combination of dose measurements, monitoring of the associated processing parameters used to achieve those doses, and procedural controls are critical in establishing a process and determining whether or not it is in a state of control.

4.2 Use of the dose measurement at the monitoring location

4.2.1 General

Analysis of measurements from routine monitoring dosimeters is used to determine whether or not process specifications have been met. There are two methods of analysis that can be considered:

- 1) interpretation of dose measurements as a direct or indirect measure of dose delivered to product; and
- 2) interpretation of dose measurements to monitor that a process is in a state of control.

In all cases, a validated process provides an expectation of the monitored dose based on derived process target doses and associated processing parameters. The interpretation of the monitoring dose should be documented in the process specification.

The ability to detect changes in the process is limited by the intrinsic variability of dose at the routine monitoring location i.e., the variability measured when the process is in control. If σ_{rep} of the monitoring dosimetry system is large or dosimeter placement imprecise, this variability might be significantly higher than the true variability of the process. In such circumstances, significant changes in the process could go undetected, because they are masked by the high intrinsic variability at the monitoring location. Steps should be taken to minimise variability arising from the monitoring dosimetry system and dosimeter placement. (See 6.5.4 and A.4)

4.2.2 D_{mon} as an indirect measurement of dose to product

In an indirect measurement, the maximum and minimum doses to product are calculated from the monitoring dose measurement. The calculated doses have uncertainties associated with the dose at the monitoring location as well as the uncertainty associated with the dose at maximum or minimum locations and associated ratios, plus any other

applicable components of uncertainty. A combination of these components can be used to determine the maximum and minimum targets for the routine monitoring dose. (See 6.5.2, 6.5.3, A.2, A.3, and A.6)

4.2.3 D_{mon} as a process monitor

It is acceptable to monitor a process where the maximum or minimum dose to product is not measured routinely (directly or indirectly), but rather where a range of monitoring doses are established that indicate that the process meets specification. In this situation, the variability associated with the measurement of minimum and maximum doses from PQ, combined with other relevant components of uncertainty can be used in determining maximum and minimum targets for the routine monitoring dose. The variability of dose at the monitoring location is then used to determine the acceptable range of doses that indicate that the process is in a state of control and meets process specifications. Because the routine monitoring dosimeter is not used to measure minimum or maximum dose to product, the uncertainty associated with the relationship between the monitored dose and the maximum and minimum doses within a process load has no relevance in determining process target doses and process conformance.

4.2.4 D_{min} or D_{max} as a direct measurement of dose to product

When routine dose is measured at the minimum and/or maximum dose location in the process load, then the dosimeter measurement provides a direct measurement of dose to product. It can also be used as an indicator that the process is in control. In such case, the benefits of both 4.2.2 and 4.2.3 might be achieved. (See A.3)

There are circumstances where a limited amount of data is available to predict the outcome of a process. An example of this is an off-carrier process which is based on a single dose map (see 6.4.1). In these cases, enough dosimeters need to be placed on products to provide a direct measurement of minimum and maximum dose.

4.3 Monitoring of critical process parameters

An important consideration in process control is the ability to detect if a processing parameter is changing in a manner that can affect the output of the process. The ability to monitor and/or control process parameters critical to the process output is, therefore, an important factor in ensuring the state of control of the irradiation process.

There are three main classes of processing parameters to be considered: parameters that relate to the radiation field, parameters that relate to the exposure time of the product to the radiation field, and parameters that relate to product influence. Table 1 provides an overview of the effect of critical process parameters and how they could be monitored.

Table 1—Process parameters critical to radiation sterilization

Parameter	Effect	Monitoring	Gamma	Electron	X-ray
Radiation field					
Radioisotope decay	Over time the radiation intensity is reduced	Source decay occurs based on the half-life of the isotope; date of irradiation is recorded	✓		
Electron energy	Energy affects the penetration depth of electrons, scan width, and also X-ray conversion efficiency	Irradiator parameters associated with input power and beam current are monitored; indirect measurements using beam penetration profiles are made periodically as part of a quality control check		✓	✓
Beam current	A change in beam current will lead to a change in the radiation intensity and possibly of the beam energy	Can be monitored indirectly during operation; indirect monitors can be calibrated		✓	✓
Beam scan width	For scanned system, width will affect the size of the radiation field and a reduction in width will increase the radiation intensity	Monitored indirectly by feedback of scanning system, or directly through interception of the beam, or through periodic dosimetric tests		✓	✓
<Tbl_row_break></Tbl_row_break>Exposure time					
Cycle time	Dose is directly proportional to cycle time. An increase in cycle time equals an increase in dose.	Cycle time is set by operator, recorded as part of the process and associated timers are calibrated	✓		✓
Conveyor speed	Dose is inversely proportional to speed of product travelling through an irradiation field	Feedback from conveyor speed monitors; direct measurements made during periodic tests	✓	✓	✓
Product influence					
Loading pattern	Changes to loading pattern including product orientation inside a carton and/or carton loading into an irradiation container can affect dose delivery	Defined product loading patterns and procedures to ensure products are loaded according to specification	✓	✓	✓
Density and loading pattern of surrounding materials	Materials surrounding product during irradiation can affect dose delivered through attenuation or scattering of radiation	Appropriate scheduling of process loads; defined criteria resulting from OQ for materials surrounding product during irradiation are documented	✓	✓	✓

5 Establishing process target doses

5.1 Inputs and steps in establishing a process target dose

5.1.1 General

The irradiation process is monitored using processing parameters and dosimeter measurements. Three process target doses at the routine monitoring position can be defined; $D_{\text{target}}^{\text{lower}}$, $D_{\text{target}}^{\text{upper}}$ and D_{target} corresponding, respectively, to

the lower and upper set limits for the process target dose and the actual process target dose chosen for processing under given conditions.

There are a number of factors used in the determination of a range of process target doses.

The inputs and steps in establishing a process target dose are listed in the following sections and depicted in Figure 1.




Figure 1—Inputs and steps in establishing a process target dose

5.1.2 Process validation inputs (installation, operational and performance qualification)

The results of process validation that can be used to provide input into establishing process target doses include the following:

- the magnitude of minimum dose to product $D_{\min}$ for a given loading configuration and set of operating parameters and its relationship to the routine monitoring dose D_{mon} ;
- the magnitude of maximum dose to product $D_{\max}$ for a given loading configuration and set of operating parameters and its relationship to the routine monitoring dose D_{mon} ;
- the variability associated with $D_{\min}$, $D_{\max}$ and D_{mon} , and the uncertainty associated with their ratios (if used);

and if applicable the effects of:

- process interruptions;
- transitions between different product;
- partially filled irradiation containers.

The application of process validation data in establishing process target doses is discussed further in 5.2.

5.1.3 Additional inputs

Additional inputs may include components that contribute to the uncertainty of the process which are not captured during process validation. These might include, but are not limited to σ_{cal} , and/or targeting buffers defined by the operator as applicable.